The Health and Human Services Department, led by vaccine skeptic Robert F. Kennedy Jr., has canceled $766 million in payments to develop a vaccine against pandemic flu viruses.

Moderna, Inc. (NASDAQ:MRNA) today announced that it had voluntarily withdrawn the pending Biologics License Application (BLA) seeking approval for its COVID-19 and Influenza combination vaccine for adults aged 50 years and older.

Moderna isn’t giving up on the combo shot entirely—it plans to resubmit later this year after it collects more data from its Phase III trials, which test how well a new treatment works compared to existing options.

Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are healthy.

HHS has terminated contracts with Moderna worth more than $700 million that were meant to fund the company’s development of pre-pandemic influenza vaccines, including the company’s H5 bird flu vaccine candidate.

A combination shot for flu and Covid-19 using messenger RNA generated antibodies in a study, but US government regulators want to see data on whether the new vaccine protects people from getting sick.

Moderna CFO Jamey Mock told Barron’s it would still be possible, despite the cuts. Mock said that while the company has cut back significantly on its capacity to put vaccine doses in vials, it ...

The $590 million contract, signed days before Trump took office, was scrapped by Health Secretary Robert F. Kennedy Jr, who has spent decades promoting misinformation about immunization.

Trump administration cancels $766 million funding for Moderna's bird flu vaccine, despite promising interim trial results.

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services terminated a contract with drugmaker Moderna to develop an mRNA bird flu vaccine,